Humanwell Healthcare Group and Commonwealth Serum Laboratories (CSL) launched a joint investment project on Aug 4. The two will invest in Wuhan Zhong Yuan Rui De Biological Products (Ruide) in Optics Valley, Wuhan.

The project aims to develop Ruide into a manufacturer of blood products and vaccines with global influence, as well as being the fourth-largest blood products manufacturing base for CSL, after the United States, Switzerland and Germany. 

CSL is a leading global biotechnology company and the largest blood products manufacturer in the world, with a focus on development, production, and sales of protein drugs, as well as treatment and prevention of serious diseases.

With investment of 352 million yuan ($ 52.38 million), CSL is to bring world-class manufacturing technologies, quality systems and reserves of blood products to Ruide, helping it reach the world's highest standards in plasma collection and production. 

CSL will further invest in Ruide to improve the manufacturing and quality of its products. 

As the headquarters for CSL in China, Biolake in Optics Valley will attract investment from the world's top blood product companies.